Navigation Links
New, No-Swallow Fasprin(R) Reduces Problems Associated with Daily Aspirin Regimen
Date:11/13/2007

Fast-dissolve method uses the latest advancement in aspirin delivery

technology.

CLEVELAND, Nov. 13 /PRNewswire/ -- Improvita Health Products, Inc. has rolled out Fasprin(R), a patented, 81 milligram aspirin tablet that dissolves rapidly in the mouth instead of in the stomach, offering an effective, simplified solution for the millions of Americans who maintain a daily aspirin routine and worry about gastrointestinal bleeding or swallowing pills.

A daily low-dose aspirin therapy is commonly prescribed to adults to prevent heart attack and stroke and help improve blood flow to the heart. Small daily doses of aspirin have proven to be effective in reducing the chances of mini-strokes (in which clogged blood vessels prevent sufficient oxygen from reaching the brain). Aspirin is also used to reduce the risk of heart attack in people with clogged coronary arteries, and in those who've already had an attack.

With its great-tasting "citrus burst" flavor, Fasprin is ideal for patients on a daily heart health aspirin regimen and is sugar free for diabetics.

Fasprin's patented, no-swallow aspirin delivery method reduces irritation to the gastrointestinal tract by quickly dissolving in the mouth, which allows the aspirin to enter the blood stream in just three to five minutes, or up to ten times faster than conventional aspirin that typically is absorbed through the stomach.

Tom Klamet, president of Improvita Health Products, Inc., noted that the low-dose aspirin tablet uses the latest technology for delivering the required dosage to the blood stream. "Fasprin was developed by a physician who saw the many benefits of an aspirin that could be administered quickly and effortlessly," he commented. "A daily aspirin regimen can fast become a chore, especially for older adults who have a hard time swallowing a full tablet. Fasprin's ability to dissolve on the tongue ensures 100 percent bioavailability, or the delivery of the entire aspirin into the blood stream."

Some studies have shown that enteric-coated aspirin delivers just 50 percent of the dosage before the remaining tablet is eliminated by the body.

The quick-dissolve absorption also makes Fasprin the delivery of choice at the onset of a heart attack or stroke, where doctors recommend immediately administering aspirin. By doing so, aspirin can reduce the risk of death by as much as 23 percent, according to published studies.

Fasprin comes in a 30-tablet package (a month's supply), and carries a suggested retail price of $5.99. Fasprin is available wherever aspirin is sold, including Walgreens, CVS, Rite Aid, Albertsons, Meijer and Wal-Mart. The product is also available through the company's website at http://www.Fasprin.com.

[Product photos and additional stories available at http://www.improvita.com/fasprin-news.]

Contact:

Steve Corcoran

Vice President

Hybrid Marketing

Phone: 216-774-9274

Cell: 440-655-6073

corc@hybridmar.com

Tom Klamet

President

Improvita Health Products, Inc.

Phone: (216) 573-1850

tklamet@improvita.com


'/>"/>
SOURCE Improvita Health Products, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. New study: Pine bark reduces perimenopausal symptoms
2. Different method of evaluating the urinary tract system reduces radiation dose
3. Saline Reduces Mortality for Brain Injury Patients
4. New study: Pine bark extract reduces ADHD symptoms in children
5. Radiation therapy technique reduces length of prostate cancer treatment
6. Radiation therapy technique reduces length of prostate cancer treatment
7. MR spectroscopy identifies breast cancer, reduces biopsies
8. Body-mind meditation boosts performance, reduces stress
9. Parkinsons Institute research shows that nicotine reduces levodopa-induced dyskinesias
10. VIDEO from Medialink and EcoQuest: New Technology Reduces Exposure to MRSA Staph
11. Ranexa(R) Significantly Reduces Incidence of CV Death, MI or Recurrent Ischemia in MERLIN TIMI-36 Patients With Elevated BNP
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2017)... ... ... enough sleep affects much more than energy – it also has mental and physical benefits. ... motor reaction time, which can increase the risk of having a car accident. , ... the NSF to help you sleep better and feel better:, , ...
(Date:4/28/2017)... ... April 28, 2017 , ... ... http://www.wiredlifesolutions.com , “Computers are everywhere and they’re here to stay,” said ... Global Climate Change and Your Health on Voice America sponsored by Nature’s Tears® ...
(Date:4/28/2017)... (PRWEB) , ... April 28, 2017 , ... The ... board members and officers for 2017-2018. The annual board election process has been in ... a volunteer basis. , Thomas C. Dickerson, Ed.D., FACHE, succeeds Jim Hamilton, MHA, CMM, ...
(Date:4/28/2017)... ... April 28, 2017 , ... Children and adolescents who ... experiences than children in the general population. That’s because foster care is designed ... family challenges. While no fault of their own, youth who have experienced trauma ...
(Date:4/28/2017)... Harbor, Md. (PRWEB) , ... April 28, 2017 ... ... Care Association of America (UCAOA) and College of Urgent Care Medicine will host ... 2017 workshops, sessions and speakers will help those in the industry adapt to ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 2017  AbbVie (NYSE: ABBV), a global biopharmaceutical ... chronic hepatitis C virus (HCV) infected patients with ... compensated cirrhosis (Child-Pugh A) achieved sustained virologic response ... its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). These ... 12 weeks of G/P treatment without ribavirin. Patients ...
(Date:4/20/2017)... Sweden , April 20, 2017 ... NEVPF) ("NeuroVive") today announced positive preclinical results ... preclinical compound for non-alcoholic steatohepatitis (NASH), in ... NV556 has previously shown ... NASH model. Today, NeuroVive,s scientists present novel ...
(Date:4/19/2017)... , April 19, 2017 Cardiology devices segment ... projected period The Cardiology Devices segment is likely ... US$ 15 Mn in 2018 over 2017. By the end ... market valuation close to US$ 700 Mn, expanding at a ... segment dominated the Asia Pacific reprocessed ...
Breaking Medicine Technology: